Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupranolol SCHEMBL29518497 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL34061 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL2497819 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL6508337 | 1.00 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL348360 | 0.99 | L3MBTL1 (0.65) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL348362 | 0.99 | L3MBTL1 (0.65) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| SCHEMBL348361 | 0.92 | L3MBTL1 (0.63) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL8908385 | 0.90 | L3MBTL1 (0.53) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| Bupranolol SCHEMBL19816741 | 0.89 | LMNA (0.55) | L3MBTL1MEN1HTTKMT2ANPSR1 | |
| SCHEMBL12215557 | 0.88 | SLC2A1 (0.57) | L3MBTL1MEN1HTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20240301022-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | UNIV ASTON (GB) | 2024-09-12 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| EP-3072978-B1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-07-11 | — | — | EP | claimed |
| CN-107753471-A | A kind of pharmaceutical composition for treating obesity-related hypertension patient and preparation method thereof | 郭裴哲 | 2018-03-06 | — | — | CN | claimed |
| EP-2336359-B1 | 1L1RL-1 as a cardiovascular disease marker | BRIGHAM & WOMENS HOSPITAL (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2488204-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2016-04-06 | — | — | EP | claimed |
| EP-2268612-B1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | claimed |
| EP-2586401-B1 | Implantable film/mesh composite | COVIDIEN LP (US) | 2014-03-19 | — | — | EP | claimed |
| EP-0229947-B1 | NOVEL CRYSTALLINE SALTS OF ARYLOXY-PROPANOLAMINES, THEIR PREPARATION AND THEIR USE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-03-13 | — | — | EP | claimed |
| EP-0384266-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0384267-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0036138-B2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1989-10-25 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0229947-A1 | Novel crystalline salts of aryloxy-propanolamines, their preparation and their use | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-07-29 | — | — | EP | claimed |
| EP-0073819-B1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | The University of Kentucky Research Foundation (US) | 1987-05-27 | — | — | EP | claimed |
| EP-0186019-A2 | Medicated dressing | SCHWARZ PHARMA AG (DE) | 1986-07-02 | — | — | EP | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |